Comparative oncology, a field of great interest to research specialists in human and veterinary medicine, is focused on comparing cancer data from canine and human patients to identify shared features that may advance our understanding of cancer in both species.
This “One Medicine/ One Health” investigative approach is the basis of the new Consortium for Canine Comparative Oncology, a collaboration between NC State University’s College of Veterinary Medicine and the Duke Cancer Institute. NC State’s CVM and Duke have joined forces to further explore new cancer therapies offering better efficacy and less toxicity for both humans and canines.
Researchers at both institutions are studying naturally occurring cancers in humans and canines and this collaboration will allow investigators to leverage research and resources to benefit both species, ensuring better treatments and outcomes.
“The ultimate goal is to improve the quality of cancer research being performed at both universities, and to foster new collaborations that lead to highly innovative approaches aimed at eradicating cancer,” says Paul Lunn, CVM dean. “There are phenomenal opportunities for this unique partnership, with huge promises for animals and people.”
Related to the creation of the Consortium for Canine Comparative Oncology, the CVM and Duke Cancer Institute are hosting a symposium from 8 a.m. to 5:30 p.m. Friday, March 4 at the North Carolina Biotechnology Center in Research Triangle Park, NC.
Panel discussions will include researchers from the two founding partner institutions as well as scientists from National Human Genome Institute, the National Cancer Institute, Purdue, Cornell, Colorado State, University of California-Davis, and the American College of Veterinary Internal Medicine (Oncology). Amy LeBlanc, director of the Comparative Oncology Program at the National Cancer Institute is the keynote speaker.